BMO Capital Markets restated their sell rating on shares of Eli Lilly and Company (NYSE:LLY) in a research note issued to investors on Friday. They currently have a $73.00 price objective on the stock.

Several other brokerages also recently issued reports on LLY. Zacks Investment Research raised Eli Lilly and from a hold rating to a buy rating and set a $96.00 price target for the company in a report on Wednesday, April 12th. Piper Jaffray Companies reiterated a buy rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Monday, April 17th. Cowen and Company increased their price objective on Eli Lilly and from $85.00 to $95.00 and gave the stock an outperform rating in a research report on Monday, April 17th. Morgan Stanley cut Eli Lilly and from an overweight rating to an equal weight rating and set a $82.00 price objective on the stock. in a research report on Monday, April 17th. Finally, Citigroup Inc. reiterated a buy rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, April 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. Eli Lilly and presently has a consensus rating of Hold and a consensus target price of $88.27.

Shares of Eli Lilly and (LLY) traded up 0.46% during trading on Friday, reaching $82.31. 2,802,610 shares of the company were exchanged. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The stock has a market capitalization of $86.84 billion, a price-to-earnings ratio of 35.62 and a beta of 0.34. The company has a 50 day moving average price of $82.99 and a 200-day moving average price of $81.53.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the firm posted $0.86 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts predict that Eli Lilly and will post $4.16 EPS for the current year.

WARNING: “Eli Lilly and Company (LLY) Receives Sell Rating from BMO Capital Markets” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/06/eli-lilly-and-company-lly-receives-sell-rating-from-bmo-capital-markets.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

In related news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock worth $55,845,287 over the last ninety days. 0.20% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in LLY. Federated Investors Inc. PA raised its stake in Eli Lilly and by 11.0% in the second quarter. Federated Investors Inc. PA now owns 229,704 shares of the company’s stock valued at $18,904,000 after buying an additional 22,811 shares during the period. Pax World Management LLC raised its stake in Eli Lilly and by 11.4% in the second quarter. Pax World Management LLC now owns 7,795 shares of the company’s stock valued at $642,000 after buying an additional 800 shares during the period. Boston Family Office LLC raised its stake in Eli Lilly and by 0.9% in the second quarter. Boston Family Office LLC now owns 10,580 shares of the company’s stock valued at $871,000 after buying an additional 90 shares during the period. Marshall Wace North America L.P. raised its stake in Eli Lilly and by 571.7% in the second quarter. Marshall Wace North America L.P. now owns 387,014 shares of the company’s stock valued at $31,735,000 after buying an additional 329,393 shares during the period. Finally, Investment Management of Virginia LLC raised its stake in Eli Lilly and by 1.0% in the second quarter. Investment Management of Virginia LLC now owns 11,645 shares of the company’s stock valued at $958,000 after buying an additional 110 shares during the period. 75.48% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.